Divi's Lab.

Who are in the management team of Divi's Lab.?

As of March 2022, the management team of Divi's Lab includes Murali K Divi (Chairman & Managing Director), Kiran S Divi (CEO), and several other directors and independent members responsible for the company's strategic direction.

As of March 2022, the management team of Divi's Lab includes the following key individuals:<BR><BR>1. Murali K Divi - Chairman & Managing Director<BR>2. N V Ramana - Executive Director<BR>3. Madhusudana Rao Divi - Whole Time Director (Projects)<BR>4. Kiran S Divi - Whole Time Director & CEO<BR>5. Nilima Motaparti - Whole Time Director - Commercial<BR>6. G Suresh Kumar - Independent Director<BR>7. Ranga Rao Ravipati - Independent Director<BR>8. K V K Seshavataram - Independent Director<BR>9. Ramesh B V Nimmagadda - Chairman (Non-Executive) & Independent Director<BR>10. S Ganapaty - Independent Director<BR>11. Sunaina Singh - Independent Director<BR>12. Kosaraju Veerayya Chowdary - Independent Director<BR>13. Satish Choudhury - Company Secretary & Compliance Officer<BR><BR>This team is responsible for the strategic direction and management of the company.

What does Divi's Lab. do?

Divi's Laboratories Limited is a prominent pharmaceutical company specializing in the manufacture of Active Pharmaceutical Ingredients (APIs), Intermediates, and Nutraceuticals. As of March 2025, it reported net sales of ₹2,585 Cr and a net profit of ₹662 Cr, with a market cap of ₹173,306 Cr.

Overview:<BR>Divi's Laboratories Limited is a leading pharmaceutical company engaged in the manufacture of Active Pharmaceutical Ingredients (APIs), Intermediates, and Nutraceuticals, operating within the Pharmaceuticals & Biotechnology industry and classified as a Large Cap company.<BR><BR>History:<BR>Divi's Laboratories was incorporated in the year 1990. The latest quarterly results reported are for March 2025, showcasing the company's ongoing operations and market presence.<BR><BR>Financial Snapshot:<BR>- Net Sales: 2,585 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 662 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: Rs 173,306 Cr (Large Cap)<BR><BR>Key Metrics:<BR>- P/E: 80.00<BR>- Industry P/E: 35<BR>- Dividend Yield: 0.45%<BR>- Debt-Equity: -0.25<BR>- Return on Equity: 14.64%<BR>- Price to Book: 11.74<BR><BR>Contact Details:<BR>Address: 1-72-23(P)/DIVIS/303 Divi Tower, Cyber Hills Gachibowli Hyderabad Telangana : 500032<BR>Tel: 91-40-23786300/23786352/400<BR>Email: mail@divislabs.com<BR>Website: http://www.divislaboratories.com

What is the bonus history of the Divi's Lab.?

Divi's Laboratories has a history of issuing bonus shares, with the most recent being a 1:1 bonus announced on September 23, 2015, and a prior 1:1 bonus on August 1, 2009. This reflects the company's consistent practice of rewarding shareholders.

Divi's Laboratories has a history of issuing bonuses. The most recent bonus was a 1:1 bonus issue, which was announced with an ex-date of September 23, 2015, and the record date was September 26, 2015. Prior to that, the company also issued a 1:1 bonus on August 1, 2009, with an ex-date of July 30, 2009. This indicates that Divi's Lab has a consistent practice of rewarding its shareholders through bonus shares.

Has Divi's Lab. declared dividend?

Divis Laboratories Ltd has declared a 1500% dividend, amounting to ₹30 per share, with an ex-date of August 2, 2024. The company has shown strong total returns over various periods, particularly with a 169.61% total return over the past five years.

Divis Laboratories Ltd has declared a 1500% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 1500%<BR>- Amount per share: 30<BR>- Ex-date: 02 Aug 24<BR><BR>Dividend Yield: 0.45%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 5.9%, the dividend return was 0%, resulting in a total return of 5.9%.<BR><BR>Over the past year, the price return was 45.73%, the dividend return was 0.67%, leading to a total return of 46.4%.<BR><BR>In the 2-year period, the price return was 84.08%, the dividend return was 1.67%, culminating in a total return of 85.75%.<BR><BR>For the 3-year period, the price return was 85.98%, the dividend return was 2.50%, resulting in a total return of 88.48%.<BR><BR>In the last 4 years, the price return was 52.87%, the dividend return was 2.55%, leading to a total return of 55.42%.<BR><BR>Over the past 5 years, the price return was 164.6%, the dividend return was 5.01%, resulting in a total return of 169.61%.<BR><BR>Overall, Divis Laboratories Ltd has declared a significant dividend, and the total returns over various periods indicate strong performance, particularly in the long term, with substantial price appreciation and increasing dividend contributions.

Who are the peers of the Divi's Lab.?

Divi's Lab. peers include Sun Pharma, Cipla, Torrent Pharma, Dr Reddy's Labs, Mankind Pharma, Zydus Lifesci., Lupin, Aurobindo Pharma, Abbott India, and Alkem Lab. Divi's Lab. has the highest 1-year return at 51.69% among its peers, while Zydus Lifesci. has the lowest at -10.04%.

Peers: The peers of Divi's Lab. are Sun Pharma.Inds., Cipla, Torrent Pharma, Dr Reddy's Labs, Mankind Pharma, Zydus Lifesci., Lupin, Aurobindo Pharma, Abbott India, and Alkem Lab.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Torrent Pharma, Dr Reddy's Labs, Mankind Pharma, Zydus Lifesci., Aurobindo Pharma, Abbott India, and Alkem Lab., while Average management risk is found at Lupin. Growth is excellent at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Mankind Pharma, Zydus Lifesci., and Lupin, while Divi's Lab., Torrent Pharma, and Aurobindo Pharma show below average growth. Excellent capital structure is noted for Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, Mankind Pharma, Zydus Lifesci., Aurobindo Pharma, and Abbott India, while good capital structure is found at Torrent Pharma and Lupin.<BR><BR>Return Snapshot: Divi's Lab. has a 1-year return of 51.69%, which is the highest among its peers, while Zydus Lifesci. has the lowest at -10.04%. Additionally, peers with negative six-month returns include Sun Pharma.Inds., Cipla, Torrent Pharma, Mankind Pharma, Zydus Lifesci., Lupin, Aurobindo Pharma, and Alkem Lab.

Who are the top shareholders of the Divi's Lab.?

The top shareholders of Divi's Lab include promoter Nilima Prasad Divi with 20.34%, foreign institutional investors holding 18.01%, mutual funds at 12.83%, and the Life Insurance Corporation of India as the largest public shareholder with 5.63%. Individual investors own 7.17% of the shares.

The top shareholders of Divi's Lab include the promoters, who hold the majority of the shares. Notably, Nilima Prasad Divi is the promoter with the highest holding at 20.34%. In addition, foreign institutional investors (FIIs) hold 18.01% of the shares, while mutual funds collectively account for 12.83% through 39 schemes. The highest public shareholder is the Life Insurance Corporation of India, which holds 5.63%. Individual investors also have a stake, representing 7.17% of the total shares.

How big is Divi's Lab.?

As of 24th July, Divis Laboratories Ltd has a market capitalization of 176,072.00 Cr, with recent net sales of 9,360.00 Cr and a net profit of 2,191.00 Cr. The company has shareholder's funds of 14,969.00 Cr and total assets of 16,921.00 Cr.

As of 24th July, Divis Laboratories Ltd has a market capitalization of 176,072.00 Cr, categorizing it as a Large Cap company.<BR><BR>In the latest four quarters, Divis Laboratories reported net sales of 9,360.00 Cr and a net profit of 2,191.00 Cr.<BR><BR>For the latest annual period ending March 2025, the company has shareholder's funds amounting to 14,969.00 Cr and total assets of 16,921.00 Cr.

When is the next results date for Divi's Lab.?

Divi's Lab. will announce its results on 07 November 2025.

Divi's Lab. will declare its results on 07 November 2025.

How has been the historical performance of Divi's Lab.?

Divi's Lab has shown consistent growth in net sales and profitability, with net sales increasing from 4,946.26 Cr in Mar'19 to 9,360.00 Cr in Mar'25, and profit after tax rising to 2,191.00 Cr in Mar'25. The company's total assets also grew significantly, reflecting a strong financial performance overall.

Answer:<BR>The historical performance of Divi's Lab shows a consistent growth trend in net sales and profitability over the years.<BR><BR>Breakdown:<BR>Divi's Lab has demonstrated a steady increase in net sales, rising from 4,946.26 Cr in Mar'19 to 9,360.00 Cr in Mar'25. The total operating income followed a similar trajectory, reaching 9,360.00 Cr in Mar'25, up from 7,767.00 Cr in Mar'23. Operating profit (PBDIT) also saw fluctuations, peaking at 3,995.81 Cr in Mar'22 before settling at 3,320.00 Cr in Mar'25. Profit before tax increased to 2,916.00 Cr in Mar'25 from 2,163.00 Cr in Mar'24, while profit after tax reached 2,191.00 Cr in Mar'25, up from 1,600.00 Cr in Mar'24. The company's total assets grew significantly from 8,531.32 Cr in Mar'20 to 16,921.00 Cr in Mar'25, reflecting a robust expansion. Total liabilities also increased, but at a slower pace, indicating a strengthening balance sheet. Cash flow from operating activities improved to 1,653.00 Cr in Mar'25, contributing to a net cash inflow of 50.00 Cr for the year. Overall, Divi's Lab has shown resilience and growth in its financial performance across multiple metrics.

Is Divi's Lab. technically bullish or bearish?

As of December 1, 2025, Divi's Lab shows a mildly bullish trend, supported by bullish weekly MACD and Bollinger Bands, despite mixed signals from monthly indicators.

As of 1 December 2025, the technical trend for Divi's Lab has changed from bullish to mildly bullish. The weekly MACD remains bullish, while the monthly MACD is mildly bearish, indicating mixed signals. The Bollinger Bands are mildly bullish on both weekly and monthly time frames, supporting a positive outlook. Daily moving averages are bullish, reinforcing the mildly bullish stance. However, the KST shows a bullish weekly trend but is mildly bearish monthly, and Dow Theory indicates no clear trend on both weekly and monthly charts. Overall, the current technical stance is mildly bullish, driven by the weekly MACD and Bollinger Bands, despite some bearish signals on the monthly indicators.

Are Divis Laboratories Ltd latest results good or bad?

Divi's Laboratories Ltd reported a 12.29% year-on-year revenue growth, but faced a concerning 15.38% decline in net profit quarter-on-quarter, indicating mixed performance. While operating margins improved, the profit drop raises questions about the company's near-term sustainability.

Divi's Laboratories Ltd's latest results reveal a mixed performance. While the company reported a year-on-year revenue growth of 12.29%, its net profit saw a significant decline of 15.38% quarter-on-quarter, dropping to ₹583 crores. This decline in profit is concerning, especially since it follows a strong profit increase in the previous quarter.<BR><BR>The revenue for the quarter ended December 2025 was ₹2,604 crores, which is a decrease of 4.09% from the previous quarter. Despite this sequential decline, the year-on-year growth indicates that the company is still managing to expand its sales compared to the same period last year.<BR><BR>On a positive note, the operating margin improved to 34.18%, reflecting strong operational efficiency. However, the overall picture is clouded by the profit decline and the challenges the company faces in a competitive market, including pricing pressures and changing demand patterns.<BR><BR>In summary, while Divi's Laboratories shows strong operational metrics and year-on-year revenue growth, the sequential profit decline raises concerns about its near-term performance and sustainability of growth.

Should I buy, sell or hold Divis Laboratories Ltd?

Why is Divis Laboratories Ltd falling/rising?

As of 17-Mar, Divis Laboratories Ltd's stock price is rising to 6,094.00, driven by increased investor interest and strong fundamentals, including a high return on equity and consistent profit growth. The stock has outperformed benchmarks and shows a solid market position, contributing to its upward trend.

As of 17-Mar, Divis Laboratories Ltd's stock price is rising, currently at 6,094.00, with a change of 19.1 (0.31%) upwards. This increase can be attributed to several factors. The stock has been gaining for the last two days, showing a return of 0.44% during this period. Additionally, there has been a rise in investor participation, with delivery volume increasing by 3.24% compared to the 5-day average, indicating growing interest among investors.<BR><BR>Despite trading lower than its moving averages across various time frames, the company has demonstrated strong fundamentals, including a high return on equity (ROE) of 17.24% and consistent positive results over the last six quarters, with a profit after tax (PAT) growth of 22.45%. Furthermore, the stock has outperformed the benchmark Sensex over the long term, generating a 7.51% return over the past year and significantly outperforming the BSE500 in the last three years.<BR><BR>The company's solid market position, being the second largest in its sector with a market cap of Rs 1,60,489 crore, and high institutional holdings at 39.36% also contribute to its rising stock price. These institutional investors typically have better resources to analyze the company's fundamentals, which can positively influence stock performance. Overall, the combination of recent gains, strong financial performance, and increased investor interest supports the upward movement in Divis Laboratories Ltd's stock price.

Why is Divis Laboratories Ltd falling/rising?

As of 18-Mar, Divis Laboratories Ltd's stock price is rising to 6,137.45, reflecting a 0.86% increase. This upward trend is supported by strong financial performance, including consistent profit growth and a high return on equity, despite some concerns regarding trading below moving averages and declining investor participation.

As of 18-Mar, Divis Laboratories Ltd's stock price is rising, currently at 6,137.45, with a change of 52.55 (0.86%) upward. This increase can be attributed to several factors. The stock has outperformed its sector by 0.59% today and has shown a consecutive gain over the last three days, rising by 1.15% during this period. Additionally, the company has demonstrated strong financial performance, with positive results for the last six consecutive quarters, including a significant growth in profit after tax (PAT) of 20.77% over the latest six months.<BR><BR>Moreover, Divis Laboratories has a high return on equity (ROE) of 17.24% and a low debt-to-equity ratio, indicating strong management efficiency and financial stability. The stock's long-term performance is also noteworthy, having generated a return of 6.22% over the past year and outperforming the BSE500 index over the last three years, one year, and three months.<BR><BR>However, it is important to note that the stock is trading below its moving averages across various time frames, which may indicate some underlying weakness. Additionally, there has been a decline in investor participation, with delivery volume falling by 13.59% against the five-day average. Despite these concerns, the overall positive financial metrics and recent performance suggest that the stock is currently on an upward trend.

Why is Divis Laboratories Ltd falling/rising?

As of 19-Mar, Divis Laboratories Ltd's stock price is falling, currently at Rs 6,007.00, reflecting a decline after three days of gains. The stock's recent performance shows a significant drop compared to benchmarks, with ongoing concerns about long-term growth and high valuation contributing to the bearish sentiment.

As of 19-Mar, Divis Laboratories Ltd's stock price is falling, currently at Rs 6,007.00, which reflects a decrease of Rs 137.8 or 2.24%. This decline follows a trend reversal after three consecutive days of gains. The stock has also touched an intraday low of Rs 5,955, marking a drop of 3.09% during the day.<BR><BR>The stock's performance over the past week shows a decline of 4.29%, which is worse than the benchmark Sensex's drop of 2.40%. Over the past month, Divis Laboratories has decreased by 4.55%, while the Sensex has fallen by 10.05%. Year-to-date, the stock is down 6.06%, compared to a 12.92% decline in the Sensex. Despite a positive annual return of 3.12%, the stock's performance is overshadowed by its recent downward trend.<BR><BR>Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish sentiment. The broader sector of Pharmaceuticals & Drugs has also experienced a decline of 2.11%, contributing to the negative sentiment surrounding Divis Laboratories.<BR><BR>While there are positive factors such as high management efficiency, consistent positive results over the last six quarters, and strong institutional holdings, these have not been sufficient to counteract the current downward price movement. The company’s long-term growth concerns, reflected in its annual sales growth of only 9.44% and operating profit growth of 4.68% over the last five years, further exacerbate the situation. The stock's high valuation, indicated by a Price to Book Value of 10.3 and a PEG ratio of 2.8, suggests that it is trading at a premium compared to its peers, which may deter investors.<BR><BR>In summary, the combination of recent price declines, underperformance relative to benchmarks, and concerns over long-term growth and valuation are contributing to the falling stock price of Divis Laboratories Ltd.

Why is Divis Laboratories Ltd falling/rising?

As of 20-Mar, Divis Laboratories Ltd's stock price is rising to 6,109.55, driven by strong management efficiency, consistent positive results, and high institutional holdings. However, it is trading below moving averages and experiencing reduced investor participation, indicating potential volatility.

As of 20-Mar, Divis Laboratories Ltd's stock price is rising, currently at 6,109.55, reflecting a change of 131.95 (2.21%) upward. This increase can be attributed to several factors. Firstly, the stock has outperformed its sector by 0.51% today and reached an intraday high of Rs 6180, which is a 3.39% increase. Additionally, the company has demonstrated strong management efficiency, with a high return on equity (ROE) of 17.24%, and has consistently reported positive results for the last six consecutive quarters, including a significant growth in profit after tax (PAT) of 22.45% over the last nine months.<BR><BR>Moreover, Divis Laboratories has a low debt-to-equity ratio, indicating financial stability, and high institutional holdings at 39.36%, suggesting confidence from larger investors who can analyze the company's fundamentals more effectively than retail investors. The stock has also shown market-beating performance in the long term, generating a 4.99% return over the past year, which is in contrast to the Sensex's decline of 2.38% during the same period.<BR><BR>However, it is important to note that while the stock is currently rising, it is trading below its moving averages across various time frames, indicating potential volatility. Additionally, there has been a significant drop in investor participation, with delivery volume falling by 57.52% against the five-day average. Despite these concerns, the positive financial metrics and recent performance contribute to the stock's upward movement.

Which are the latest news on Divi's Lab.?